KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2025)

Historic Intangibles for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Q3 2025 value amounting to $111.6 million.

  • Acadia Pharmaceuticals' Intangibles rose 578.12% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 578.12%. This contributed to the annual value of $119.8 million for FY2024, which is 8290.12% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Intangibles stood at $111.6 million for Q3 2025, which was up 578.12% from $114.3 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Intangibles ranged from a high of $119.8 million in Q4 2024 and a low of $369000.0 during Q2 2021
  • For the 4-year period, Acadia Pharmaceuticals' Intangibles averaged around $81.4 million, with its median value being $105.5 million (2024).
  • In the last 5 years, Acadia Pharmaceuticals' Intangibles plummeted by 8001.08% in 2021 and then soared by 8290.12% in 2024.
  • Acadia Pharmaceuticals' Intangibles (Quarter) stood at $369000.0 in 2021, then skyrocketed by 17647.97% to $65.5 million in 2023, then soared by 82.9% to $119.8 million in 2024, then dropped by 6.82% to $111.6 million in 2025.
  • Its last three reported values are $111.6 million in Q3 2025, $114.3 million for Q2 2025, and $117.1 million during Q1 2025.